On August 31, 2022, Shimazu, Yutaka; Murata, Makoto; Kondo, Takeshi; Minami, Yosuke; Tachibana, Takayoshi; Doki, Noriko; Uchida, Naoyuki; Ozawa, Yukiyasu; Yano, Shingo; Fukuda, Takahiro; Kato, Jun; Ara, Takahide; Eto, Testuya; Ishikawa, Jun; Nakamae, Hirohisa; Tanaka, Junji; Ichinohe, Tatsuo; Atsuta, Yoshiko; Nagamura-Inoue, Tokiko; the working group of the Japan Society for Transplantation and Cellular Therapy published an article.Product Details of 380843-75-4 The title of the article was The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. And the article contained the following:
The introduction of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) treatment has dramatically improved the prognosis of CML patients and reduced the number of patients receiving allogeneic stem cell transplantation (allo-SCT). However, the impact of the newest-generation TKIs on the overall survival (OS) after allo-SCT has not been well described. To investigate the beneficial effects of TKIs on the prognosis after allo-SCT, we conducted a retrospective observational study using the Transplant Registry Unified Management Program database in Japan. We analyzed 1188 patients (male/female: 738/450; median age: 44 years; range: 16-75) who underwent their first allo-SCT between Jan. 2001 and Dec. 2018. We divided the patients into two groups according to the TKI treatment used before allo-SCT: group 1 was treated with the first generation TKI imatinib; group 2 was treated with the second generation TKIs nilotinib, dasatinib, or bosutinib and/or the third generation TKI ponatinib. We compared the post allo-SCT OS between the two groups. The 3-yr OS rates (95%CI) of groups 1 and 2 were 59.3% (54.8%-63.5%) and 65.8% (61.6%-69.6%), resp. (p = 0.017). Multivariate anal. confirmed that group 2 had superior OS after allo-SCT compared to group 1 (p = 0.002). Other factors associated with superior prognosis were age ≤65, performance status (PS) 0/1, a 6/6 HLA-matched donor and chronic-phase (CP) disease status at allo-SCT. A subgroup anal. showed poor prognoses for patients who could not obtain a mol. response before allo-SCT and patients with pos. T315I mutation in the BCR/ABL gene. In group 2, early allo-SCT was correlated with superior OS in patients with a blast-crisis disease status at allo-SCT (p = 0.001). The cumulative incidence of non-relapse mortality rate significantly decreased in group 2 (p = 0.0005). The post allo-SCT OS was improved both by pre- and post-management of allo-SCT and by the introduction of newer TKIs. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Product Details of 380843-75-4
The Article related to tyrosine kinase inhibitor allogenic stem cell transplantation myeloid leukemia, allogeneic stem cell transplantation, chronic myeloid leukemia, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Product Details of 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics